A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 791,504 shares of BLUE stock, worth $348,261. This represents 0.0% of its overall portfolio holdings.

Number of Shares
791,504
Previous 2,187,700 63.82%
Holding current value
$348,261
Previous $2.8 Million 72.32%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$0.85 - $1.26 $1.19 Million - $1.76 Million
-1,396,196 Reduced 63.82%
791,504 $775,000
Q1 2024

May 13, 2024

SELL
$0.91 - $1.75 $410,410 - $789,250
-451,000 Reduced 17.09%
2,187,700 $2.8 Million
Q4 2023

Feb 13, 2024

BUY
$1.32 - $4.83 $2.86 Million - $10.5 Million
2,163,800 Added 455.63%
2,638,700 $3.64 Million
Q3 2023

Nov 14, 2023

SELL
$3.02 - $4.05 $227,406 - $304,965
-75,300 Reduced 13.69%
474,900 $1.44 Million
Q2 2023

Aug 11, 2023

BUY
$2.79 - $5.03 $1.54 Million - $2.77 Million
550,200 New
550,200 $1.81 Million
Q3 2022

Nov 14, 2022

SELL
$3.75 - $7.39 $7.7 Million - $15.2 Million
-2,052,890 Reduced 73.06%
757,110 $4.79 Million
Q2 2022

Aug 12, 2022

BUY
$2.94 - $5.23 $5.5 Million - $9.78 Million
1,870,000 Added 198.94%
2,810,000 $11.6 Million
Q1 2022

May 13, 2022

BUY
$4.07 - $10.6 $3.83 Million - $9.96 Million
940,000 New
940,000 $4.56 Million
Q1 2021

May 13, 2021

SELL
$16.59 - $33.89 $10 Million - $20.5 Million
-603,700 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$27.5 - $37.92 $10.7 Million - $14.8 Million
389,300 Added 181.58%
603,700 $26.1 Million
Q3 2020

Nov 13, 2020

BUY
$34.44 - $43.75 $7.38 Million - $9.38 Million
214,400 New
214,400 $11.6 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $33.9M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.